Clinical guidelines should establish clear timelines, and health care systems should prioritize timely treatment initiation and completion,” researchers concluded.

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European ...

Enliven Therapeutics, Inc. (Enliven or the Company) , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company ...

Tim Cavanaugh, who has worked with some of the biggest names in comedy, thought he may never walk, much less make jokes, ...

today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025). The studies demonstrate how Volition's Nu.Q ...

Session Date and Time: Monday, April 28, 2:00 - 5:00 p.m.

According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy and safety profile with IV pembrolizumab.

today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 ...

MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to ...